Navigation Links
Zogenix Increases Series B Preferred Stock Financing to $71 Million, Raising $35 Million in Second Tranche
Date:12/7/2009

SAN DIEGO, Dec. 7, /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, announced today that it has closed a $35 million second tranche of a Series B preferred stock financing. The Series B round was increased from $51 million, previously announced in September, to $71 million. The additional $20 million investment was made by Chicago Growth Partners, which will now be represented on the Zogenix Board of Directors by Dr. Arda Minocherhomjee. All existing Zogenix investors including Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, and Abingworth Management, as well as new investor, Oxford Finance Corporation, contributed to the total $71 million Series B.

The capital primarily will be used to fully support the launch of SUMAVEL(TM) DosePro(TM) (sumatriptan injection) needle-free delivery system, the company's first product, that will launch in January 2010. Zogenix is also advancing its product pipeline and is actively engaged in efforts to out-license the unique, needle-free DosePro technology to other biopharmaceutical companies.

"Zogenix has developed an innovative product by incorporating a needle-free delivery system, which potentially could also be used for a variety of pharmaceuticals," said Dr. Minorcherhomjee. "The company has a strong management team and board, and is well positioned to capture share in select market segments."

"We are very pleased to welcome Chicago Growth Partners to our investor group and also very fortunate to have the continued support from all of our existing investors," said Roger Hawley, CEO, Zogenix. "Our dedicated Zogenix team is on track with all aspects of our commercial plan, including building our sales force. Zogenix will be fully prepared for our first launch in January. These are exciting times, and I'm proud of our team's accomplishments."

About DosePro technology

The DosePro technology is an easy-to-use, pre-filled drug delivery system designed to enable self-administration of single doses of liquid drug formulations, subcutaneously, without a needle. The DosePro technology has undergone more than ten years of design, process engineering, clinical evaluation and development work. DosePro is protected by more than 80 patents, issued and applied for, worldwide. Approximately 9,000 injections have been delivered in clinical trials in healthy volunteers using the DosePro needle-free drug delivery system.

About Zogenix

Zogenix, Inc., with offices in Emeryville and San Diego, Calif., is a privately held pharmaceutical company focused on the development and commercialization of medicines to treat neuroscience disorders and pain. The company's initial focus is the commercialization of SUMAVEL DosePro. Zogenix submitted a New Drug Application with the U.S. Food and Drug Administration for SUMAVEL DosePro in December 2007, and received FDA approval in July 2009. The company's pipeline also includes ZX002, a novel oral controlled-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain, preparing to enter Phase 3 clinical trials. Zogenix also plans to license the patented DosePro needle-free drug delivery system to other companies. For additional information, visit www.zogenix.com.

Zogenix(TM), Sumavel(TM) and DosePro(TM) are trademarks of Zogenix, Inc.

SOURCE Zogenix, Inc.


'/>"/>
SOURCE Zogenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL(TM) DosePro(TM)
2. Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)
3. Diffusion tensor imaging increases ability to remove benign tumors in children
4. Gene increases effectiveness of drugs used to fight cancer and allows reduction in dosage
5. Fat around the middle increases the risk of dementia
6. The Institute of Women's Health of North America Increases its Outreach by Offering Free and Confidential HIV Testing in Florida
7. Highlighting racial disparities increases coverage and effectiveness of health news
8. Why Watching TV Sports Increases Heart Attacks
9. Migraine Increases Likelihood of Stroke
10. Mesa Labs Increases Quarterly Dividend
11. Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... and ranked among the top US security companies for consecutive years, today announced ... announcement brings a year-long independent board nomination process to a close and positions ...
(Date:1/17/2017)... ... 17, 2017 , ... Today, FloSports , a global leader in live ... as part of a long-term extension of their media partnership. The partnership, which began ... of the sport’s premier events exclusively on FloWrestling.com as well as usage of the ...
(Date:1/16/2017)... ... January 17, 2017 , ... To provide comfort ... leader in the fast-casual category, announces a hearty and wholesome Winter Menu. Starting ... Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked Smoky Chicken ...
(Date:1/16/2017)... ... , ... California Southern University has named Dr. Steven Beazley University President. ... as a core faculty member, teaching master’s and doctoral courses in the university’s School ... University, where he earned his Doctor of Psychology degree in 1998. Dr. Beazley also ...
(Date:1/16/2017)... Elk Grove Village, IL (PRWEB) , ... January ... ... protection and personal audio products, will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic ... Expo and Convention Center in Las Vegas, Booth #2809. The SHOT Show is ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , January 17, 2017 ... 2016;11(Suppl. 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... Published recently in European Neurological ... touchNEUROLOGY, Catherine Amey reports that despite ...
(Date:1/17/2017)... , Jan. 17, 2017  Tetra Discovery ... M. Erwin as Vice President, Clinical Operations. ... he was Executive Director, Clinical Project Management. ... years of experience in global clinical research planning ... successful growth-stage clinical operation build-outs and development partnerships," ...
(Date:1/17/2017)... WHIPPANY, N.J. , Jan. 17, 2017  Bayer today ... President of its Pharmaceuticals business in the Americas, comprising ... , Central and Latin America . In ... , member of the Board of Management of Bayer AG ... a strategic and highly respected leader in the pharmaceutical industry ...
Breaking Medicine Technology: